Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $11.00.
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 6th.
Read Our Latest Stock Report on Evaxion A/S
Evaxion A/S Stock Performance
Shares of NASDAQ:EVAX traded up $0.03 during trading on Friday, hitting $2.83. 74,536 shares of the company were exchanged, compared to its average volume of 44,088. The company has a market cap of $25.53 million, a PE ratio of -2.34 and a beta of 0.50. The stock has a 50 day moving average of $3.14 and a 200 day moving average of $3.46. Evaxion A/S has a 52-week low of $2.72 and a 52-week high of $9.50. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06.
Institutional Investors Weigh In On Evaxion A/S
Several hedge funds and other institutional investors have recently modified their holdings of EVAX. Rathbones Group PLC purchased a new stake in shares of Evaxion A/S in the first quarter worth about $170,000. Renaissance Technologies LLC purchased a new position in Evaxion A/S during the first quarter valued at approximately $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S during the first quarter valued at approximately $112,000. 11.04% of the stock is currently owned by institutional investors.
About Evaxion A/S
Evaxion A/S is a Denmark-based biotechnology company developing artificial intelligence-driven immunotherapies. The company’s technology is designed to identify disease-specific targets, known as antigens, and support the development of personalized treatments that stimulate a patient’s immune system to recognize and attack diseased cells or pathogens.
Evaxion’s research programs have focused primarily on personalized cancer immunotherapies, including EVX-01, as well as vaccines and immunotherapies for infectious diseases caused by bacteria and viruses.
See Also
- Five stocks we like better than Evaxion A/S
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
